Press releases

Granulomatose septique chronique : des bio-marqueurs pour prédire l’efficacité de la thérapie génique

Sorry, this entry is only available in French. [credits]©Unsplash[/credits]Les services cliniques de l’Hôpital Necker-Enfants malades AP-HP en collaboration étroite avec des équipes de l'AP-HP,  de l'Inserm et d'Université Paris ...
Press release | 07 Feb 2023 | Genetics, genomics and bioinformatics

Defeating leukaemia cells by depriving them of energy

A Swiss-French team that includes UNIGE scientists has discovered how to trigger apoptosis in leukaemia cells by disrupting their energy maintenance mechanism. ...
Press release | 17 Feb 2022 |

La prise du traitement du VIH intermittente aussi efficace qu’une prise quotidienne chez les patients traités

Parmi les pistes explorées pour améliorer la tolérance des traitements antirétroviraux (ARV) chez les personnes vivant avec le VIH (PVVIH), ainsi que la réduction des coûts, le projet ANRS 170 QUATUOR a étudié la prise du traitement ARV quatre jours par semaine ...
Press release | 15 Feb 2022 | Immunology, inflammation, infectiology and microbiology Public health

Règles éthiques et volontaires sains : l’Inserm organise une rencontre entre les acteurs internationaux de la recherche biomédicale

Devenir acteur de la recherche pour contribuer à faire avancer les connaissances et trouver de nouveaux traitements est l'un des « leitmotiv » des personnes, malades ou non, qui participent aux essais cliniques. Les volontaires ont toujours joué un rôle capital ...
Press release | 14 Feb 2022 | Institutional and special event Public health

A Novel Immunotherapy Approach Redirects Epstein-Barr Antibodies toward Disease-Causing Cells

Monoclonal antibody therapy can be very effective in treating numerous illnesses, such as cancers, chronic inflammatory conditions, and infectious diseases. Researchers from Inserm, Université de Paris, Sorbonne Université and CNRS1 have designed and tested a new immunotherapy approach that uses pre-existing antibodies ...
Press release | 11 Feb 2022 | Cancer Immunology, inflammation, infectiology and microbiology

A Gene Therapy Studied in Steinert's Disease

Myotonic dystrophy type 1 (DM1) or Steinert’s disease is a rare and debilitating genetic neuromuscular disease affecting multiple organs and with a fatal outcome. No treatment is available at present. Encouraged by previous research into its molecular causes, researchers have developed and ...
Press release | 10 Feb 2022 | Molecular and structural bases of living organisms Genetics, genomics and bioinformatics

Inserm Signs Its First Contract of Objectives, Means and Performance with the French State

"A new impetus for health biology research." This is the ambition of Inserm’s Contract of Objectives, Means and Performance signed on Friday, February 4, 2022. ...
Press release | 10 Feb 2022 | Institutional and special event
fermer
fermer
RSS Youtube